Skip to main content
  • Engineering any genome, at any site, in any way

  • At the forefront of a revolutionary field offering profound benefits to human health and society

  • Focused on the advancement of new applications for CRISPR-based technologies

  • Exploring the vast potential of CRISPR-Cas technology across therapeutics, agricultural biotech, biological research and industrial biotech


The Jackson Laboratory and Caribou Biosciences Announce CRISPR-Cas9 License Agreement

October 25, 2016
Bar Harbor, ME and Berkeley, CA – Caribou Biosciences, Inc. and The Jackson Laboratory (JAX) announced an agreement today whereby Caribou has granted JAX non-exclusive worldwide rights to use its CRISPR-Cas9 intellectual property to create...

Caribou Biosciences’ President and CEO Rachel Haurwitz Named to Fortune’s 2016 “40 under 40” List of Most Influential Young People in Business

September 26, 2016
BERKELEY, CA – September 26, 2016 – Caribou Biosciences, Inc., a developer of CRISPR-Cas technologies for genome engineering, announced today that Rachel Haurwitz, Ph.D., President and Chief Executive Officer, has been selected for Fortune...

Our Approach

Caribou Biosciences is a pioneer in the revolutionary field of CRISPR-Cas genome editing.  Our proprietary technology puts us at the forefront of the development of new medical therapies and bio-based products which offer profound benefits to both human health and society as a whole. 

Our singular focus is on the advancement of new applications for CRISPR-Cas gene editing that will help bring the tremendous promise this technology holds for patients and consumers to reality.

Learn More...